Quick Answer
NovoCure Ltd reported Long-Term Debt of $568.82 million for fiscal year 2023.
NovoCure Ltd Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2023 | $568.82M | +0.6% |
| 2022 | $565.51M | +0.6% |
| 2021 | $562.22M | +30.8% |
| 2020 | $429.90M | +187.7% |
| 2019 | $149.42M | +0.1% |
| 2018 | $149.27M | +53.3% |
| 2017 | $97.34M | +1.2% |
| 2016 | $96.23M | +316.6% |
| 2015 | $23.10M | — |
| 2014 | $0.00 | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| March 31, 2024 | $569.65M | +0.6% | +0.1% |
| December 31, 2023 | $568.82M | +0.6% | +0.1% |
| September 30, 2023 | $567.99M | +0.6% | +0.1% |
| June 30, 2023 | $567.15M | +0.6% | +0.1% |
| March 31, 2023 | $566.32M | +0.6% | +0.1% |
| December 31, 2022 | $565.51M | +0.6% | +0.1% |
| September 30, 2022 | $564.68M | +0.6% | +0.1% |
| June 30, 2022 | $563.85M | +0.6% | +0.1% |
- NovoCure Ltd showed an increase of +0.6% in Long-Term Debt compared to the prior fiscal year.
- The most recent figure is from NovoCure Ltd’s fiscal year 2023 report (Form 10-K), filed with the SEC on February 22, 2024.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: